Celularity Inc.
CELUHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Celularity Inc. (CELU) is listed under Biotechnology. Valued at $48.6M, CELU is a micro-cap name in its sector. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Market Cap
$48.6M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-2.95
EPS (TTM)
$-3.59
EPS (Fwd)
$-0.57
ROE
—
ROA
-30.9%
Cash
$6.2M
Total Debt
$74.7M
Free CF
$5.4M
52W Change
-25.7%
Annual Financials
Cash vs Debt
Where CELU stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CELU finished 82.35% above its 150-day moving average ($1.02) and 63.16% above its 200-day moving average ($1.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CELU overbought or oversold?
At the September 3, 2026 close, CELU's RSI(14) was 75.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Celularity Inc. carries $74.7M in total debt against $6.2M in cash reserves — debt is roughly 12.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $5.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has grown from $18.0M (2022) to $26.6M (2025), reflecting a 48% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Celularity Inc.'s trajectory.